Incidence, prevalence, and outcomes of systemic malignancy with bone metastases

Jiang, Wenli; Rixiati, Youlutuziayi; Zhao, Bingqing; Li, Yongcheng; Tang, Cheng; Liu, Jun

doi:10.1177/2309499020915989

Cited by 42 publications

(33 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Widespread disparities in cancer incidence, prevalence, mortality, survival, morbidity, survivorship, financial burden of disease, screening rates and stage distribution at diagnosis have been reported 1 . However, there are no reports addressing disparities in the incidence of MBD 10–14 . The National Institute of Minority Health and Health Disparities defined health disparities research to encompass health differences in socially disadvantaged populations and specific outcomes, including: (1) higher incidence or prevalence; (2) earlier or higher mortality rate; (3) increased global burden of disease; (4) poorer health behaviors and clinical outcomes related to the previous outcomes; (5) worse outcomes on validated and specific patient reported outcome measures 15 .…”

Section: Introductionmentioning

confidence: 99%

“…1 However, there are no reports addressing disparities in the incidence of MBD. [10][11][12][13][14] The National Institute of Minority Health and Health Disparities defined health disparities research to encompass health differences in socially disadvantaged populations and specific outcomes, including: (1) higher incidence or prevalence; (2) earlier or higher mortality rate; (3) increased global burden of disease; (4) poorer health behaviors and clinical outcomes related to the previous outcomes; (5) worse outcomes on validated and specific patient reported outcome measures. 15 This report describes sex, racial, and socioeconomic disparities in the incidence of MBD originating from the five most common anatomical sites.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Sex, racial/ethnic and socioeconomic disparities in patients with metastatic bone disease

Jawad

Pollock

Zeitlinger

et al. 2021

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background: We have analyzed sex, race/ethnicity or socioeconomic disparities in the incidence of metastatic bone disease (MBD).Methods: Patients with the diagnosis of MBD at presentation for five most common primary anatomical sites was extracted from Surveillance, Epidemiology, and EndResults Census tract-level dataset. Mean incidence of MBD for different sex, racial/ ethnic and socioeconomic groups were compared. Results:The five most common anatomical sites with MBD at presentation include "lung: (n = 59 739), "prostate" (n = 19 732), "breast" (n = 16 244), "renal" (n = 7718) and "colon" (n = 3068). There was an increase in incidence of MBD among cancers originating from prostate (annual percentage change [APC] 4.94), renal (APC 2.55), and colon (APC 3.21) (p < 0.05 for all). Non-Hispanic Blacks had higher incidence of MBD for prostate and breast primary sites (p < 0.001). Non-Hispanic American Indian Alaskan Native had higher incidence of MBD for cancers originating from renal (p < 0.001) and colon (p = 0.049). A higher incidence of MBD was seen in lower socioeconomic status (SES) groups for the selected sites (p < 0.001).Conclusions: These findings suggest that there are multiple sex-related, racial/ethnic and SES disparities in the incidence of MBD from the 5 most common primary sites.Higher incidence seen among lower SES suggests delay in diagnosis and limited access to screening modalities.

show abstract

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

Sex, racial/ethnic and socioeconomic disparities in patients with metastatic bone disease

Jawad

Pollock

Zeitlinger

et al. 2021

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…22 While a number of decision aids have been proposed or developed for the management of cancer in general, there are no decision support tools specifically designed for the management of symptomatic bone metastases, 23 despite the prevalence of bony metastatic disease. For example, a recent SEER analysis demonstrates that approximately 30% of cases of metastatic cancer have bone metastases, 24 although rates may be as high as 75% in post-mortem studies of advanced breast and prostate cancers. 25 Unlike, available educational material and consensus guidelines available in this clinical setting, an optimal decision support tool would provide individualised estimates of patient survival time, magnitude of the relative efficacy and risks of available treatment regimens, and assessment of patient preference.…”

Section: Introductionmentioning

confidence: 99%

Improving providers' survival estimates and selection of prognosis‐ and guidelines‐appropriate treatment for patients with symptomatic bone metastases: Development of the Bone Metastases Ensemble Trees for Survival Decision Support Platform

Alcorn

Elledge

LaVigne

et al. 2022

Evaluation Clinical Practice

View full text Add to dashboard Cite

Rationale, Aims and Objectives: In the management of symptomatic bone metastases, current practice guidelines do not provide clear methodology for selecting palliative radiotherapy (RT) regimens based on specific patient and disease features. Decision support aids may offer an effective means for translating the complex data needed to render individualised treatment decisions, yet no such tools are available for use in this setting. Thus, we describe the development of the Bone Metastases Ensemble Trees for Survival-Decision Support Platform (BMETS-DSP), which aims to optimise selection of evidence-based, individualised palliative RT regimens. Method: The Ottawa Decision Support Framework was used as the theoretical basis for development of BMETS-DSP. First, we utilised stakeholder input and review of the literature to assess determinants underlying the provider decision. Based on this assessment and iterative stakeholder feedback, we developed the web-based, provider-facing BMETS-DSP. Consistent with the underlying theoretical framework, our design also included assessment of decision quality using the International Patient Decision Aids Standards (IPDAS) certification checklist. Results: Stakeholder input and review of 54 evidence-based publications identified the following determinants of the provider decision: estimated prognosis, characteristics of the target symptomatic lesion and the primary cancer type, consideration of alternative interventions, access to patient-specific recommendations, and patient preferences. Based on these determinants, we developed the BMETS-DSP that (1) collects patient-specific data, (2) displays an individualised predicted survival curve, and (3) provides case-specific, evidence-based recommendations regarding RT, open surgery, systemic therapy, and hospice referral to aid in the

show abstract

“…The most common cause of osteoblastic metastases is prostate cancer, but other tumor types such as lung cancer, breast cancer, or bladder cancer can cause these lesions as well (12). Like osteoporosis, vertebral metastases lead to an increased risk of VFs, which can cause severe pain, limb dysfunction, and spinal cord compression, thus markedly affecting the patients' quality of life (1,13).…”

Section: Introductionmentioning

confidence: 99%

Finite Element Analysis of Osteoporotic and Osteoblastic Vertebrae and Its Association With the Proton Density Fat Fraction From Chemical Shift Encoding-Based Water-Fat MRI – A Preliminary Study

et al. 2022

View full text Add to dashboard Cite

PurposeOsteoporosis is prevalent and entails alterations of vertebral bone and marrow. Yet, the spine is also a common site of metastatic spread. Parameters that can be non-invasively measured and could capture these alterations are the volumetric bone mineral density (vBMD), proton density fat fraction (PDFF) as an estimate of relative fat content, and failure displacement and load from finite element analysis (FEA) for assessment of bone strength. This study’s purpose was to investigate if osteoporotic and osteoblastic metastatic changes in lumbar vertebrae can be differentiated based on the abovementioned parameters (vBMD, PDFF, and measures from FEA), and how these parameters correlate with each other.Materials and MethodsSeven patients (3 females, median age: 77.5 years) who received 3-Tesla magnetic resonance imaging (MRI) and multi-detector computed tomography (CT) of the lumbar spine and were diagnosed with either osteoporosis (4 patients) or diffuse osteoblastic metastases (3 patients) were included. Chemical shift encoding-based water-fat MRI (CSE-MRI) was used to extract the PDFF, while vBMD was extracted after automated vertebral body segmentation using CT. Segmentation masks were used for FEA-based failure displacement and failure load calculations. Failure displacement, failure load, and PDFF were compared between patients with osteoporotic vertebrae versus patients with osteoblastic metastases, considering non-fractured vertebrae (L1-L4). Associations between those parameters were assessed using Spearman correlation.ResultsMedian vBMD was 59.3 mg/cm3 in osteoporotic patients. Median PDFF was lower in the metastatic compared to the osteoporotic patients (11.9% vs. 43.8%, p=0.032). Median failure displacement and failure load were significantly higher in metastatic compared to osteoporotic patients (0.874 mm vs. 0.348 mm, 29,589 N vs. 3,095 N, p=0.034 each). A strong correlation was noted between PDFF and failure displacement (rho -0.679, p=0.094). A very strong correlation was noted between PDFF and failure load (rho -0.893, p=0.007).ConclusionPDFF as well as failure displacement and load allowed to distinguish osteoporotic from diffuse osteoblastic vertebrae. Our findings further show strong associations between PDFF and failure displacement and load, thus may indicate complimentary pathophysiological associations derived from two non-invasive techniques (CSE-MRI and CT) that inherently measure different properties of vertebral bone and marrow.

show abstract

Incidence, prevalence, and outcomes of systemic malignancy with bone metastases

Cited by 42 publications

References 17 publications

Sex, racial/ethnic and socioeconomic disparities in patients with metastatic bone disease

Sex, racial/ethnic and socioeconomic disparities in patients with metastatic bone disease

Improving providers' survival estimates and selection of prognosis‐ and guidelines‐appropriate treatment for patients with symptomatic bone metastases: Development of the Bone Metastases Ensemble Trees for Survival Decision Support Platform

Finite Element Analysis of Osteoporotic and Osteoblastic Vertebrae and Its Association With the Proton Density Fat Fraction From Chemical Shift Encoding-Based Water-Fat MRI – A Preliminary Study

Contact Info

Product

Resources

About